814 related articles for article (PubMed ID: 26205347)
41. The biological properties of different Epstein-Barr virus strains explain their association with various types of cancers.
Tsai MH; Lin X; Shumilov A; Bernhardt K; Feederle R; Poirey R; Kopp-Schneider A; Pereira B; Almeida R; Delecluse HJ
Oncotarget; 2017 Feb; 8(6):10238-10254. PubMed ID: 28052012
[TBL] [Abstract][Full Text] [Related]
42. Cordycepin enhances Epstein-Barr virus lytic infection and Epstein-Barr virus-positive tumor treatment efficacy by doxorubicin.
Du Y; Yu J; Du L; Tang J; Feng WH
Cancer Lett; 2016 Jul; 376(2):240-8. PubMed ID: 27063964
[TBL] [Abstract][Full Text] [Related]
43. Pulse inhibition of histone deacetylases induces complete resistance to oxidative death in cortical neurons without toxicity and reveals a role for cytoplasmic p21(waf1/cip1) in cell cycle-independent neuroprotection.
Langley B; D'Annibale MA; Suh K; Ayoub I; Tolhurst A; Bastan B; Yang L; Ko B; Fisher M; Cho S; Beal MF; Ratan RR
J Neurosci; 2008 Jan; 28(1):163-76. PubMed ID: 18171934
[TBL] [Abstract][Full Text] [Related]
44. Microtubule depolymerization activates the Epstein-Barr virus lytic cycle through protein kinase C pathways in nasopharyngeal carcinoma cells.
Liu YR; Huang SY; Chen JY; Wang LH
J Gen Virol; 2013 Dec; 94(Pt 12):2750-2758. PubMed ID: 24062531
[TBL] [Abstract][Full Text] [Related]
45. The Epstein-Barr virus (EBV)-encoded protein kinase, EBV-PK, but not the thymidine kinase (EBV-TK), is required for ganciclovir and acyclovir inhibition of lytic viral production.
Meng Q; Hagemeier SR; Fingeroth JD; Gershburg E; Pagano JS; Kenney SC
J Virol; 2010 May; 84(9):4534-42. PubMed ID: 20181711
[TBL] [Abstract][Full Text] [Related]
46. Cytolytic virus activation therapy for Epstein-Barr virus-driven tumors.
Wildeman MA; Novalic Z; Verkuijlen SA; Juwana H; Huitema AD; Tan IB; Middeldorp JM; de Boer JP; Greijer AE
Clin Cancer Res; 2012 Sep; 18(18):5061-70. PubMed ID: 22761471
[TBL] [Abstract][Full Text] [Related]
47. The cellular ataxia telangiectasia-mutated kinase promotes epstein-barr virus lytic reactivation in response to multiple different types of lytic reactivation-inducing stimuli.
Hagemeier SR; Barlow EA; Meng Q; Kenney SC
J Virol; 2012 Dec; 86(24):13360-70. PubMed ID: 23015717
[TBL] [Abstract][Full Text] [Related]
48. BZLF1 controlled by family repeat domain induces lytic cytotoxicity in Epstein-Barr virus-positive tumor cells.
Wang H; Zhao Y; Zeng L; Tang M; El-Deeb A; Li JJ; Cao Y
Anticancer Res; 2004; 24(1):67-74. PubMed ID: 15015577
[TBL] [Abstract][Full Text] [Related]
49. Cytotoxic effects of NF‑κB inhibitors in combination with anti‑herpes agents on Epstein‑Barr virus‑positive gastric carcinoma in vitro.
Ordonez P; Nandakumar A; Koriyama C; Yamomoto M; Akiba S
Mol Med Rep; 2016 Sep; 14(3):2359-67. PubMed ID: 27430429
[TBL] [Abstract][Full Text] [Related]
50. Efficient Translation of Epstein-Barr Virus (EBV) DNA Polymerase Contributes to the Enhanced Lytic Replication Phenotype of M81 EBV.
Church TM; Verma D; Thompson J; Swaminathan S
J Virol; 2018 Mar; 92(6):. PubMed ID: 29263273
[TBL] [Abstract][Full Text] [Related]
51. Inhibition of class I histone deacetylases in non-small cell lung cancer by honokiol leads to suppression of cancer cell growth and induction of cell death in vitro and in vivo.
Singh T; Prasad R; Katiyar SK
Epigenetics; 2013 Jan; 8(1):54-65. PubMed ID: 23221619
[TBL] [Abstract][Full Text] [Related]
52. Inhibition of the LKB1-AMPK pathway by the Epstein-Barr virus-encoded LMP1 promotes proliferation and transformation of human nasopharyngeal epithelial cells.
Lo AK; Lo KW; Ko CW; Young LS; Dawson CW
J Pathol; 2013 Jul; 230(3):336-46. PubMed ID: 23592276
[TBL] [Abstract][Full Text] [Related]
53. Pharmacologic Activation of Lytic Epstein-Barr Virus Gene Expression without Virion Production.
Lee J; Kosowicz JG; Hayward SD; Desai P; Stone J; Lee JM; Liu JO; Ambinder RF
J Virol; 2019 Oct; 93(20):. PubMed ID: 31341058
[TBL] [Abstract][Full Text] [Related]
54. Baicalein inhibits growth of Epstein-Barr virus-positive nasopharyngeal carcinoma by repressing the activity of EBNA1 Q-promoter.
Zhang Y; Wang H; Liu Y; Wang C; Wang J; Long C; Guo W; Sun X
Biomed Pharmacother; 2018 Jun; 102():1003-1014. PubMed ID: 29710517
[TBL] [Abstract][Full Text] [Related]
55. EBV Infection and Glucose Metabolism in Nasopharyngeal Carcinoma.
Zhang J; Jia L; Tsang CM; Tsao SW
Adv Exp Med Biol; 2017; 1018():75-90. PubMed ID: 29052133
[TBL] [Abstract][Full Text] [Related]
56. DNA Damage Signaling Is Induced in the Absence of Epstein-Barr Virus (EBV) Lytic DNA Replication and in Response to Expression of ZEBRA.
Wang'ondu R; Teal S; Park R; Heston L; Delecluse H; Miller G
PLoS One; 2015; 10(5):e0126088. PubMed ID: 25950714
[TBL] [Abstract][Full Text] [Related]
57. Effects of targeting sumoylation processes during latent and induced Epstein-Barr virus infections using the small molecule inhibitor ML-792.
Garcia P; Harrod A; Jha S; Jenkins J; Barnhill A; Lee H; Thompson M; Williams JP; Barefield J; Mckinnon A; Suarez P; Shah A; Lowrey AJ; Bentz GL
Antiviral Res; 2021 Apr; 188():105038. PubMed ID: 33577806
[TBL] [Abstract][Full Text] [Related]
58. Ganciclovir augments the lytic induction and apoptosis induced by chemotherapeutic agents in an Epstein-Barr virus-infected gastric carcinoma cell line.
Ji Jung E; Mie Lee Y; Lan Lee B; Soo Chang M; Ho Kim W
Anticancer Drugs; 2007 Jan; 18(1):79-85. PubMed ID: 17159505
[TBL] [Abstract][Full Text] [Related]
59. Class I and class II histone deacetylases are potential therapeutic targets for treating pancreatic cancer.
Wang G; He J; Zhao J; Yun W; Xie C; Taub JW; Azmi A; Mohammad RM; Dong Y; Kong W; Guo Y; Ge Y
PLoS One; 2012; 7(12):e52095. PubMed ID: 23251689
[TBL] [Abstract][Full Text] [Related]
60. Adenosine Induces EBV Lytic Reactivation through ADORA1 in EBV-Associated Gastric Carcinoma.
Choi SJ; Ryu E; Lee S; Huh S; Shin YS; Kang BW; Kim JG; Cho H; Kang H
Int J Mol Sci; 2019 Mar; 20(6):. PubMed ID: 30875759
[No Abstract] [Full Text] [Related]
[Previous] [Next] [New Search]
